Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 13/20 | 0.76 |
| ▸ | CHRNB2 | P17787 | 11/20 | 0.76 |
| ▸ | CHRNA4 | P43681 | 11/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL373001 | 0.85 | CHRNB2 (1.00) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL372799 | 0.84 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL373096 | 0.84 | CHRNB2 (0.76) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL372648 | 0.83 | CHRNB2 (1.00) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL1741511 | 0.83 | CHRNB2 (1.00) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL373097 | 0.83 | CHRNB2 (0.83) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL372727 | 0.83 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL372691 | 0.83 | CHRNB2 (1.00) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL373249 | 0.82 | CHRNB2 (0.79) | CHRNA7CHRNB2CHRNA4 | |
| Tc-6987 SCHEMBL1460452 | 0.82 | CHRNB2 (0.85) | CHRNA7CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084462-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100240696-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | TARGACEPT, INC. (US) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240696-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | CHRNA7, CHRNA3, CHRNA5 | CHRNA7 1/4885CHRNB2 15/4885CHRNA4 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.